CAR-T Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

Acute Lymphoblastic Leukemia (ALL) is the fastest growing segment, North America is the largest regional market

The Global CAR-T Cell Therapy Market, valued at USD 3.87 Billion in 2024, is projected to experience a CAGR of 22.77% to reach USD 13.25 Billion by 2030. Chimeric Antigen Receptor (CAR)-T cell therapy represents an advanced form of immunotherapy where a patient's T cells are genetically engineered to express a receptor targeting specific antigens on cancer cells. The market's expansion is primarily driven by the increasing global incidence of hematological malignancies, the demonstrated high efficacy and durable responses observed in relapsed or refractory patient populations, and substantial investment in research and development aimed at broadening therapeutic indications and enhancing treatment accessibility.

Key Market Drivers

The global CAR-T cell therapy market is significantly influenced by the demonstrated high efficacy of these treatments in hematologic malignancies and the expanding regulatory approvals for new indications. The proven ability of CAR-T therapies to induce deep and durable responses in patient populations with limited alternative options provides a compelling clinical rationale for their adoption and growth. For instance, according to Bristol Myers Squibb and 2seventy bio, in February 2023, the Phase 3 KarMMa-3 study demonstrated that Abecma achieved a 71% overall response rate in patients with relapsed or refractory multiple myeloma. This robust clinical performance underscores the transformative potential of CAR-T cells, driving demand and investment in this therapeutic area.

Key Market Challenges

The substantial cost associated with personalized CAR-T cell treatments represents a significant barrier to the global market's expansion. These high costs severely limit broader patient access and place considerable strain on healthcare systems, directly impeding the widespread adoption of these therapies. The financial burden creates substantial hurdles for both patients and healthcare providers, restricting the volume of treatments administered.

Key Market Trends

Expansion into Solid Tumor Indications represents a crucial diversification beyond the initial successes in hematologic malignancies, opening significant new market segments. The inherent complexities of solid tumors, such as their immunosuppressive microenvironments and heterogeneous antigen expression, have historically presented considerable challenges for CAR-T cell efficacy.

However, ongoing research and technological innovations are addressing these barriers through enhanced CAR designs, localized delivery methods, and combinatorial approaches. Progress in this area is evidenced by the growing number of clinical investigations, with solid tumors constituting 24.6% of CAR-T clinical trials as of May 2025, according to insights from Frontiers. This expansion into a broader range of cancer types is pivotal for realizing the full therapeutic and commercial potential of CAR-T cell therapy, moving it towards a more widespread application in oncology.

Key Market Players Profiled:

Gilead Sciences, Inc.
Novartis AG
Bristol-Myers Squibb Company
AbbVie Inc.
Cellectis SA
Amgen Inc.
Pfizer Inc
Merck KgaA
Intellia Therapeutics, Inc.
Johnson & Johnson

Report Scope:

In this report, the Global CAR-T Cell Therapy Market has been segmented into the following categories:

By Product Type:

Yescarta
Kymriah
Tecartus
Breyanzi
Abecma

By Tumor Type:

Hematological Malignancies
Solid Tumors

By Indication:

Diffused Large B-Cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukemia (ALL)
Follicular Lymphoma (FL)
Mantle Cell Lymphoma (MCL)
Others

By Targeted Antigen:

D 19
BCMA (B-Cell Maturation Antigen)
Others

By End User:

Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Others

By Treatment Type:

Single Treatment
Combination Treatment

By Region:

North America
Europe
Asia-Pacific
South America
Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global CAR-T Cell Therapy Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global CAR-T Cell Therapy Market Outlook

5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Yescarta, Kymriah, Tecartus, Breyanzi, Abecma)
5.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
5.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
5.2.4. By Targeted Antigen (D 19, BCMA (B-Cell Maturation Antigen), Others)
5.2.5. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
5.2.6. By Treatment Type (Single Treatment, Combination Treatment)
5.2.7. By Region
5.2.8. By Company (2024)
5.3. Market Map

6. North America CAR-T Cell Therapy Market Outlook

6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Tumor Type
6.2.3. By Indication
6.2.4. By Targeted Antigen
6.2.5. By End User
6.2.6. By Treatment Type
6.2.7. By Country
6.3. North America: Country Analysis
6.3.1. United States CAR-T Cell Therapy Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product Type
6.3.1.2.2. By Tumor Type
6.3.1.2.3. By Indication
6.3.1.2.4. By Targeted Antigen
6.3.1.2.5. By End User
6.3.1.2.6. By Treatment Type
6.3.2. Canada CAR-T Cell Therapy Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product Type
6.3.2.2.2. By Tumor Type
6.3.2.2.3. By Indication
6.3.2.2.4. By Targeted Antigen
6.3.2.2.5. By End User
6.3.2.2.6. By Treatment Type
6.3.3. Mexico CAR-T Cell Therapy Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product Type
6.3.3.2.2. By Tumor Type
6.3.3.2.3. By Indication
6.3.3.2.4. By Targeted Antigen
6.3.3.2.5. By End User
6.3.3.2.6. By Treatment Type

7. Europe CAR-T Cell Therapy Market Outlook

7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Tumor Type
7.2.3. By Indication
7.2.4. By Targeted Antigen
7.2.5. By End User
7.2.6. By Treatment Type
7.2.7. By Country
7.3. Europe: Country Analysis
7.3.1. Germany CAR-T Cell Therapy Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By Tumor Type
7.3.1.2.3. By Indication
7.3.1.2.4. By Targeted Antigen
7.3.1.2.5. By End User
7.3.1.2.6. By Treatment Type
7.3.2. France CAR-T Cell Therapy Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By Tumor Type
7.3.2.2.3. By Indication
7.3.2.2.4. By Targeted Antigen
7.3.2.2.5. By End User
7.3.2.2.6. By Treatment Type
7.3.3. United Kingdom CAR-T Cell Therapy Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product Type
7.3.3.2.2. By Tumor Type
7.3.3.2.3. By Indication
7.3.3.2.4. By Targeted Antigen
7.3.3.2.5. By End User
7.3.3.2.6. By Treatment Type
7.3.4. Italy CAR-T Cell Therapy Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product Type
7.3.4.2.2. By Tumor Type
7.3.4.2.3. By Indication
7.3.4.2.4. By Targeted Antigen
7.3.4.2.5. By End User
7.3.4.2.6. By Treatment Type
7.3.5. Spain CAR-T Cell Therapy Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product Type
7.3.5.2.2. By Tumor Type
7.3.5.2.3. By Indication
7.3.5.2.4. By Targeted Antigen
7.3.5.2.5. By End User
7.3.5.2.6. By Treatment Type

8. Asia-Pacific CAR-T Cell Therapy Market Outlook

8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Tumor Type
8.2.3. By Indication
8.2.4. By Targeted Antigen
8.2.5. By End User
8.2.6. By Treatment Type
8.2.7. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China CAR-T Cell Therapy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By Tumor Type
8.3.1.2.3. By Indication
8.3.1.2.4. By Targeted Antigen
8.3.1.2.5. By End User
8.3.1.2.6. By Treatment Type
8.3.2. India CAR-T Cell Therapy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By Tumor Type
8.3.2.2.3. By Indication
8.3.2.2.4. By Targeted Antigen
8.3.2.2.5. By End User
8.3.2.2.6. By Treatment Type
8.3.3. Japan CAR-T Cell Therapy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By Tumor Type
8.3.3.2.3. By Indication
8.3.3.2.4. By Targeted Antigen
8.3.3.2.5. By End User
8.3.3.2.6. By Treatment Type
8.3.4. South Korea CAR-T Cell Therapy Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product Type
8.3.4.2.2. By Tumor Type
8.3.4.2.3. By Indication
8.3.4.2.4. By Targeted Antigen
8.3.4.2.5. By End User
8.3.4.2.6. By Treatment Type
8.3.5. Australia CAR-T Cell Therapy Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product Type
8.3.5.2.2. By Tumor Type
8.3.5.2.3. By Indication
8.3.5.2.4. By Targeted Antigen
8.3.5.2.5. By End User
8.3.5.2.6. By Treatment Type

9. Middle East & Africa CAR-T Cell Therapy Market Outlook

9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Tumor Type
9.2.3. By Indication
9.2.4. By Targeted Antigen
9.2.5. By End User
9.2.6. By Treatment Type
9.2.7. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia CAR-T Cell Therapy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By Tumor Type
9.3.1.2.3. By Indication
9.3.1.2.4. By Targeted Antigen
9.3.1.2.5. By End User
9.3.1.2.6. By Treatment Type
9.3.2. UAE CAR-T Cell Therapy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By Tumor Type
9.3.2.2.3. By Indication
9.3.2.2.4. By Targeted Antigen
9.3.2.2.5. By End User
9.3.2.2.6. By Treatment Type
9.3.3. South Africa CAR-T Cell Therapy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By Tumor Type
9.3.3.2.3. By Indication
9.3.3.2.4. By Targeted Antigen
9.3.3.2.5. By End User
9.3.3.2.6. By Treatment Type

10. South America CAR-T Cell Therapy Market Outlook

10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Tumor Type
10.2.3. By Indication
10.2.4. By Targeted Antigen
10.2.5. By End User
10.2.6. By Treatment Type
10.2.7. By Country
10.3. South America: Country Analysis
10.3.1. Brazil CAR-T Cell Therapy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product Type
10.3.1.2.2. By Tumor Type
10.3.1.2.3. By Indication
10.3.1.2.4. By Targeted Antigen
10.3.1.2.5. By End User
10.3.1.2.6. By Treatment Type
10.3.2. Colombia CAR-T Cell Therapy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product Type
10.3.2.2.2. By Tumor Type
10.3.2.2.3. By Indication
10.3.2.2.4. By Targeted Antigen
10.3.2.2.5. By End User
10.3.2.2.6. By Treatment Type
10.3.3. Argentina CAR-T Cell Therapy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product Type
10.3.3.2.2. By Tumor Type
10.3.3.2.3. By Indication
10.3.3.2.4. By Targeted Antigen
10.3.3.2.5. By End User
10.3.3.2.6. By Treatment Type

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global CAR-T Cell Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Gilead Sciences, Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Novartis AG
15.3. Bristol-Myers Squibb Company
15.4. AbbVie Inc.
15.5. Cellectis SA
15.6. Amgen Inc.
15.7. Pfizer Inc
15.8. Merck KgaA
15.9. Intellia Therapeutics, Inc.
15.10. Johnson & Johnson

16. Strategic Recommendations17. About the Publisher & Disclaimer

Companies Mentioned

The companies profiled in this CAR-T Cell Therapy market report include:

Gilead Sciences, Inc.
Novartis AG
Bristol-Myers Squibb Company
AbbVie Inc.
Cellectis SA
Amgen Inc.
Pfizer Inc
Merck KgaA
Intellia Therapeutics, Inc.
Johnson & Johnson

Table Information

Report Attribute	Details
No. of Pages	182
Published	November 2025
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 3.87 Billion
Forecasted Market Value ( USD ) by 2030	$ 13.25 Billion
Compound Annual Growth Rate	22.7%
Regions Covered	Global
No. of Companies Mentioned	11

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4019EUR$4,500USD£3,517GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€4912EUR$5,500USD£4,299GBP